SLC12A2 and brain disorder: Our NKCC1/torsemide co-structure should inspire the development of torsemide derivatives, which may cross the blood-brain barrier more readily than the charged bumetanide molecule, to inhibit NKCC1 in the central nervous system for the treatment of various brain disorders.